Home > Boards > US OTC > Medical - Drugs >

Relief Therapeutics Holding AG (RLFTF)

Add RLFTF Price Alert      Hide Sticky   Hide Intro
Moderator: Major_Bankz, Millstone, The Whale, LETSWIN2020, Andy2018, notos
Search This Board: 
Last Post: 10/1/2020 4:50:14 AM - Followers: 406 - Board type: Free - Posts Today: 24





Rapid Recovery from COVID-19 Respiratory Failure with Comorbidity in 21 Patients Treated with Vasoactive Intestinal Peptide



8 PagesPosted: 4 Aug 2020Last revised: 20 Aug 2020

Jihad G. Youssef

Houston Methodist Research Institute

Mukhtar Al-Saadi

Houston Methodist Hospital

Faisal Zahiruddin

Houston Methodist Hospital

Sarah Beshay

affiliation not provided to SSRN

Mohammad Bitar

affiliation not provided to SSRN

Jonathan Javitt

Johns Hopkins School of Medicine

Date Written: August 20, 2020


Background: Vasoactive Intestinal Peptide (VIP) is known to bind to and protect Alveolar Type II cells by blocking replication of the SARS-CoV-2 virus, inhibiting cytokine synthesis, preventing cytopathy, and upregulating surfactant production. RLF-100™ (aviptadil), a synthetic form of VIP has been granted Fast Track Designation for treating Critical COVID-19 with Respiratory Failure and is currently in phase 2/3 placebo-controlled trials. 

Methods: Case series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP. Sixteen patients were treated with mechanical ventilation and five with extracorporeal membrane oxygenation (ECMO).

Results: So far, 19 of 21 patients have survived. Improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 patients. A mean 292% increase in PaO2:FiO2 ratio was seen with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. Three of 5 patients on ECMO have been decannulated and two have been discharged. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).  

Comment: The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.


Note: Funding: Funding:Research support was provided by the Cavendish Impact Foundation. Clinical trial funding was provided by Relief Therapeutics Holdings, AG, Geneva, which holds intellectual property related to the pharmacologic use of Aviptadil. 

Conflict of Interest: Author JCJ is employed bya pharmaceutical company that is currently conducting clinical trials of RLF-100in patients with COVID-19 and has a financial interest in the outcome of those clinical trials. Author MJJ was paid for medical writing by NeuroRx, Inc. Author JGY has received funding as an investigator for RLF-100 through his institution. 

Ethical Approval: Human subjects protection was overseen by the Institutional Review Board (IRB) of the Houston Methodist Hospital. 

Keywords: VIP, vasoactive intestinal peptide, aviptadil, SARS-CoV-2, corona virus, COVID-19, respiratory failure, IL6, ARDS

Previous News

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

August 2, 2020, 4:00 PM

- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites

- Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes

- RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol



Relief Therapeutics sees 60-70% chance of COVID-19 drug approval

AUGUST 8, 2020 / 2:52 AM

ZURICH (Reuters) - Relief Therapeutics’ chairman said he was optimistic its RLF-100 (aviptadil) drug will win approval for treating COVID-19 patients in a matter of months.

The Swiss group owns the rights to the drug in the United States and Europe. Its U.S. partner NeuroRx is running multicentre clinical trials here including a Phase IIb/III trial in patients who are severely ill because of the consequences of COVID-19, the respiratory disease caused by the new coronavirus.

“The active pharmaceutical ingredient of aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic,” Raghuram Selvaraju told Swiss newspaper The Market in an interview posted late on Friday.

“From an efficacy standpoint we need more data. I would say the probability at the moment stands at 60 to 70% that we will get the drug approved,” he added.


New York Times


FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 Patients

By Reuters

Aug. 6, 2020, 12:51 a.m. ET
  • ZURICH — The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Relief Therapeutics Holdings said on Thursday.

The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before Sept. 1, a joint statement said.

They said aviptadil is shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in the lung. It is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA fast track designation, FDA emergency use IND authorisation, and an expanded access protocol.

(Reporting by Michael Shields; editing by Thomas Seythal)


Research Paper out from JohnHopkins,Houston Methodist Hospital and
New York University (NYU) - Langone Medical Center

Rapid Recovery from COVID-19 Respiratory Failure after treatment with Vasoactive Intestinal Peptide

RLF-100 (aviptaadil) Clinical Trail - FastTrack COVID drug

Drug that gives fellas a lift in the bedroom may also beat Covid, experts believe
Fox News Affiliate Coverage on drug Aviptadil/RLF-100

Dr. Yo talks the science behind RFL-100 in latest video.





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RLFTF News: Epazz, Inc. (OTC Pink: EPAZ) - Healthcare & Government Contracts and now Education 09/22/2020 06:25:59 AM
RLFTF News: Traders News Source Identifies Tomorrows NASDAQ's 09/03/2020 08:45:00 AM
#24244  Sticky Note The test for determining if the information was The Whale 09/30/20 04:23:56 PM
#20297  Sticky Note The LifeScience video and the CEO Roundtable video Uncle Gee Gee 09/12/20 11:18:38 PM
#13538  Sticky Note Trump knows some big drugs are about to Uncle Gee Gee 08/23/20 10:28:32 PM
#3516  Sticky Note $RLFTF Phase II study where inhaled Aviptadil was Andy2018 08/09/20 06:50:41 PM
#24369   Of course! They deal at $ 0.59 this moment. go_wamu 10/01/20 04:50:14 AM
#24368   AMG was the 1st to predict Nephron Pharmaceuticals. AMG 10/01/20 04:21:33 AM
#24367   Got to admit our Swiss friends are more tiggerifficm4 10/01/20 04:19:18 AM
#24366   Wow. .534 and climbing. Woohoo. Pcilliterate 10/01/20 03:17:18 AM
#24365   I think it's just heavy sell orders because Pcilliterate 10/01/20 02:56:23 AM
#24364   So probably big news incoming. Or a securities Insightfulpenguin 10/01/20 02:51:17 AM
#24363   Trading halt message on the six. Last Pcilliterate 10/01/20 02:40:15 AM
#24362   $RLFTF Interesting post by stonkdoctor -ya ho brd mc67 10/01/20 02:35:10 AM
#24361   Ohhhhh that sounds so ominous!!! aGuyUS 10/01/20 01:26:58 AM
#24360   Nels ...yes ...a story continues but its Whalatane 10/01/20 01:26:46 AM
#24359   I agree... KIWI YOU WERE 100% Vanilla Fitbit 10/01/20 01:24:30 AM
#24358   nelskof 10/01/20 01:19:50 AM
#24357   Kiwi, you were 100% right about getting the nelskof 10/01/20 01:15:25 AM
#24356   I'm just a guy that borrowed that statement nelskof 10/01/20 01:11:39 AM
#24355   Nels. On 8/12 Dr Javitts stated Whalatane 10/01/20 01:05:18 AM
#24354   terrible delays pnnymn 10/01/20 12:48:41 AM
#24353   Yes EXACTLY. “It will be hard for them GreenKnight 10/01/20 12:46:29 AM
#24352   Well said. Appreciated. nancynande 10/01/20 12:20:24 AM
#24351   Excellent summary of the day's trading.. cybermich 10/01/20 12:16:54 AM
#24350   I had to borrow this from StonkDoctor...TY nelskof 10/01/20 12:13:38 AM
#24349   ABSOLUTELY the interview caused the Vanilla Fitbit 10/01/20 12:12:40 AM
#24348   DD Post & Some Thoughts on Today: GreenKnight 10/01/20 12:09:40 AM
#24347   OK. I guess we'll see. sommerseby 10/01/20 12:07:18 AM
#24346   CT does his video's every day! What's that aGuyUS 10/01/20 12:04:35 AM
#24345   Fair enough. But I've seen this pattern before. sommerseby 09/30/20 11:44:21 PM
#24344   It did Directly relate to the Interview...If you aGuyUS 09/30/20 11:42:06 PM
#24343   Well, with-right PR this stock can explosive. 123414 09/30/20 11:30:08 PM
#24342   Agreed. I just want people to know that sommerseby 09/30/20 11:24:57 PM
#24341   The business of the company is solid. The 123414 09/30/20 11:22:31 PM
#24340   Secondary Support Line on the $0.5300 holds the day. aGuyUS 09/30/20 11:20:56 PM
#24339   People. This had nothing to do with that sommerseby 09/30/20 11:16:49 PM
#24338   What a day. I'm holding long. 123414 09/30/20 11:11:31 PM
#24337   GEM has to make back that 18m loan Insightfulpenguin 09/30/20 11:10:19 PM
#24336   24317 Great post summary. 123414 09/30/20 11:07:38 PM
#24335   Bung-ho-li-o, No-one says you have to Buy/Hold/sell/trade this stock. tcm55 09/30/20 10:51:16 PM
#24334   Today tiggerifficm4 09/30/20 10:46:26 PM
#24333   agreed, lotta pent up demand out there, just urgonnatrip 09/30/20 10:36:59 PM
#24331   What was..date..of..this ..alert your posting 2business 09/30/20 10:32:17 PM
#24330   Panic sell off. Edny1 09/30/20 10:31:00 PM
#24329   Nope. That’s an hour or 2 north of me. Insightfulpenguin 09/30/20 10:30:47 PM
#24328   traders got in hoping for the dr to Chasing 09/30/20 10:30:22 PM
#24327   Thanks for that, great stuff. Today we urgonnatrip 09/30/20 10:30:06 PM
#24326   Wtf happened today ? Edny1 09/30/20 10:18:09 PM
#24325   Good points elllk 09/30/20 10:07:50 PM
#24324   Couldn’t the dump have been dilution? mikar 09/30/20 10:04:30 PM
#24323   Of course, I don’t know for sure what elllk 09/30/20 10:01:02 PM
#24322   Nice summary ! Well-said GreenKnight 09/30/20 09:53:59 PM
#24321   I like the way you’re thinkin’.... rewatching video... GreenKnight 09/30/20 09:51:24 PM
#24320   The predicted second wave of COVID coinciding with elllk 09/30/20 09:41:34 PM
#24319   ".20.icu..patients..sent home.." was not anything I referred to. elllk 09/30/20 09:34:55 PM
Consent Preferences